Epigenetics in renal cell cancer: mechanisms and clinical applications

@article{Joosten2018EpigeneticsIR,
  title={Epigenetics in renal cell cancer: mechanisms and clinical applications},
  author={Sophie C Joosten and Kim M. Smits and Maureen J.B. Aarts and V Melotte and Alexander Koch and Vivianne C. G. Tjan-Heijnen and Manon van Engeland},
  journal={Nature Reviews Urology},
  year={2018},
  volume={15},
  pages={430-451}
}
Renal cell carcinoma (RCC) is characterized by an infrequent number of somatic mutations. By contrast, epigenetic aberrations are commonly found in RCC, indicating that epigenetic reprogramming is an important event in RCC development. Epigenetic alterations comprise several different aberrations, such as changes in histone modifications, DNA methylation, and microRNA levels, and occur in the most important signalling pathways in RCC, such as the von Hippel–Lindau disease tumour suppressor (VHL… CONTINUE READING
BETA

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 385 REFERENCES

Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear cell renal cell carcinoma: a multicentre, singlearm phase I/II clinical trial

R Pili
  • Br. J. Cancer 116,
  • 2017

Identification of miR1953p as an oncogene in RCC

L Jin
  • Mol. Med. Rep. 15,
  • 2017